Steroid News and Research

RSS

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR).

17 Jun 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.

16 Jun 2010

BIOTRONIK announces commercial availability of new ProMRI Pacing Systems

BIOTRONIK SE & Co. KG, a leading manufacturer of high-quality implantable cardiac devices and pioneer of wireless remote monitoring technologies, announced today the commercial availability of its new ProMRI Pacing Systems — Evia pacemaker series and Safio pacing leads — providing European patients the first portfolio of bradycardia systems that are compatible with Magnetic Resonance Imaging scans under specific conditions.

15 Jun 2010

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Data presented at the 15th European Hematology Association (EHA) congress in Barcelona, highlights the impact of febrile neutropenia (FN) on chemotherapy delivery in non-Hodgkin lymphoma (NHL) patients. The IMPACT NHL study showed that unplanned hospitalisations, delays in chemotherapy and reductions of chemotherapy dose leading to suboptimal relative dose intensity (RDI) of chemotherapy were more frequent in patients who experienced FN than those who did not.

14 Jun 2010

Otonomy completes $10 million Series A financing with Avalon Ventures

Otonomy, Inc. announced today that it has completed a $10 million Series A financing with Avalon Ventures. Proceeds from the financing will be used to support the ongoing clinical trial for OTO-104 in Meniere's disease, initiate IND-enabling studies for OTO-203, and continue early-stage development of a third program.

11 Jun 2010

Harbor BioSciences closes $2.06M common stock registered direct offering

Harbor BioSciences, Inc. announced today that it has closed its previously announced sale of approximately $2.06 million of its common stock and warrants in a registered direct offering, issuance and sale to select investors.

11 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.

9 Jun 2010

Harbor BioSciences to raise $2.06M through sale of common stock shares and warrants

Harbor BioSciences, Inc. announced today that it has entered into an agreement with certain institutional investors to raise approximately $2.06 million in gross proceeds through the sale of approximately 5.9 million shares of its common stock and warrants to purchase approximately 3.5 million shares of its common stock.

7 Jun 2010

CPAP treatment may be a better option for preterm infants

A national study involving a UT Southwestern Medical Center neonatologist provides new insight into how much oxygen preterm infants should receive as well as the optimal way to deliver it to them.

3 Jun 2010

NSF International tests, certifies nutritional supplements to prevent unacceptable contaminants

Recent news coverage has consumers concerned about the alarming amount of contaminants, such as pesticides and heavy metals, being found in herbal supplements. NSF International, an independent, not-for-profit public health organization, helps ease these concerns by testing and certifying supplements to ensure they are free of undeclared substances and unacceptable contaminants.

29 May 2010

Pfizer plans recruitment halt to EMPHASIS-HF trial

Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.

27 May 2010

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.

21 May 2010

Zebrafish may help scientists reveal function of mysterious enzyme linked to steroid cortisol

Michael E. Baker, PhD, a researcher at the University of California, San Diego School of Medicine has discovered that zebrafish - an important animal model in disease and environmental studies - could provide the means to help scientists eventually reveal the function of a mysterious enzyme linked to the steroid cortisol, and found in the human brain.

20 May 2010

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent Office (USPTO) has issued a patent (US 7,704,985) entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases." The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.

19 May 2010

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

18 May 2010

Vidazorb Belly Boost probiotic supplement relieves children from eczema

May is National Asthma and Allergy Awareness Month and, though many parents deal with their kids' allergies year-round, it's a time for education on the subject. One allergic reaction to food, fabric, grass, pollen, environmental factors, etc. is eczema, which recent statistics show develops in one out of ten children before the age of five.

18 May 2010

University of Leeds researchers identify natural defence mechanism against heart disease

A natural defence mechanism against heart disease could be switched on by steroids sold as health supplements, according to researchers at the University of Leeds.

18 May 2010

Steroid News and Research

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

FDA approves Jevtana to treat men with prostate cancer

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

BIOTRONIK announces commercial availability of new ProMRI Pacing Systems

Study confirms impact of febrile neutropenia on chemotherapy delivery in NHL

Otonomy completes $10 million Series A financing with Avalon Ventures

Harbor BioSciences closes $2.06M common stock registered direct offering

Some commonly used drugs cause bone loss: New research

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Harbor BioSciences to raise $2.06M through sale of common stock shares and warrants

CPAP treatment may be a better option for preterm infants

NSF International tests, certifies nutritional supplements to prevent unacceptable contaminants

Pfizer plans recruitment halt to EMPHASIS-HF trial

Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC

Zebrafish may help scientists reveal function of mysterious enzyme linked to steroid cortisol

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Vidazorb Belly Boost probiotic supplement relieves children from eczema

University of Leeds researchers identify natural defence mechanism against heart disease

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News